Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 79 EV-to-EBIT is 6.90 as of Jul. 26, 2026, which is 12% below its 10-year median of 7.83. GuruFocus rates CHIX:BAVAC with a GF Score™ of 79/100 and a GF Value™ of kr173.46. The stock has 2 warning signs investors should review. Among 378 Biotechnology companies, Bavarian Nordic AS ranks better than 61.9% on this metric.
Bavarian Nordic AS (CHIX:BAVAc) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bavarian Nordic AS's Enterprise Value for the quarter that ended in Mar. 2026 was kr12,456 Mil.
Bavarian Nordic AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,601 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS EV-to-EBIT Related Terms
Bavarian Nordic AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's EV-to-EBIT falls into.
Bavarian Nordic AS's current Enterprise Value is kr11,045 Mil.
Bavarian Nordic AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,601 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a EV-to-EBIT of 6.90 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bavarian Nordic AS and its competitors. This is 12% below median its historical median of 7.83. According to the industry distribution chart, Bavarian Nordic AS ranks #144 out of 378 companies in the Biotechnology industry, placing it in the top 38.1%.
Is Bavarian Nordic AS's EV-to-EBIT too high?
Bavarian Nordic AS's current EV-to-EBIT of 6.90 is 12% below median its 10-year median of 7.83. The Biotechnology industry median EV-to-EBIT is 12.78. Bavarian Nordic AS's value of 6.90 is 46% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #144 out of 378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #144 out of 378 companies for EV-to-EBIT. This puts Bavarian Nordic AS in the upper half of its industry. The industry median EV-to-EBIT is 12.78. Bavarian Nordic AS's value of 6.90 is 46% below this benchmark. While the company's 10-year median is 7.83 vs. the industry median of 12.78, Bavarian Nordic AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current EV-to-EBIT of 6.90 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current EV-to-EBIT is 6.90, which is 12% below median its own 10-year median of 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current EV-to-EBIT of 6.90. The stock's GF Value™ is kr173.46, compared to a current price of kr188.30 — trading 8.6% above its estimated fair value. The current EV-to-EBIT is 6.90, which is 12% below median its 10-year median of 7.83 and 46% below the Biotechnology industry median of 12.78. Bavarian Nordic AS's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current EV-to-EBIT is 6.90 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 8.6% above its estimated GF Value™ of kr173.46.
Key valuation signals for CHIX:BAVAC:
EV-to-EBIT: 6.90 (12% below median its 10-year median of 7.83)
GF Value™: kr173.46 vs. price of kr188.30 (8.6% above fair value)
Industry Position: 46% below the Biotechnology median (#144 of 378)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score
Get the complete analysis for CHIX:BAVAC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
